Parametric Portfolio Associates LLC lifted its holdings in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,943 shares of the company’s stock after buying an additional 284 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.07% of Global Blood Therapeutics worth $846,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Global Blood Therapeutics by 15.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after buying an additional 397,271 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Global Blood Therapeutics by 76.4% in the 2nd quarter. Northern Trust Corp now owns 451,771 shares of the company’s stock worth $12,356,000 after buying an additional 195,657 shares during the last quarter. Citigroup Inc. boosted its stake in shares of Global Blood Therapeutics by 1,544.9% in the 2nd quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock worth $2,402,000 after buying an additional 82,480 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Global Blood Therapeutics by 102.7% in the 2nd quarter. New York State Common Retirement Fund now owns 39,500 shares of the company’s stock worth $1,080,000 after buying an additional 20,012 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 17.5% in the 2nd quarter. ProShare Advisors LLC now owns 25,649 shares of the company’s stock worth $702,000 after buying an additional 3,827 shares during the last quarter. Hedge funds and other institutional investors own 85.03% of the company’s stock.

WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/20/global-blood-therapeutics-inc-gbt-shares-bought-by-parametric-portfolio-associates-llc.html.

Several equities analysts recently commented on GBT shares. Wedbush reiterated an “ourperform” rating and issued a $73.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, September 18th. Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Tuesday, October 10th. Oppenheimer Holdings, Inc. set a $53.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. Morgan Stanley reiterated an “overweight” rating and issued a $56.00 price objective (up previously from $51.00) on shares of Global Blood Therapeutics in a research note on Friday, October 6th. Finally, Needham & Company LLC started coverage on Global Blood Therapeutics in a research note on Wednesday, September 20th. They issued a “buy” rating and a $51.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Global Blood Therapeutics presently has an average rating of “Buy” and an average target price of $55.00.

Shares of Global Blood Therapeutics, Inc. (GBT) opened at $40.50 on Monday. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter last year, the company earned ($0.58) EPS. analysts forecast that Global Blood Therapeutics, Inc. will post -2.53 earnings per share for the current year.

In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $35.00, for a total transaction of $437,500.00. Following the sale, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 141,655 shares in the company, valued at approximately $4,249,650. The disclosure for this sale can be found here. Insiders have sold a total of 91,500 shares of company stock worth $3,093,350 in the last three months. Insiders own 5.30% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.